Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 111Neoplasms 8Neoplasm Metastasis 6Carcinoma, Intraductal, Noninfiltrating 6Breast Carcinoma In Situ 4Arthralgia 4Advanced Breast Cancer 4Osteoporosis 2Multiple Endocrine Neoplasia Type 1 2Breast Neoplasms, Male 2Breast Cancer Metastatic 2Triple Negative Breast Neoplasms 1Sexual Dysfunction, Physiological 1Seizures 1Recurrence 1Quality of Life 1Patient Compliance 1Pain 1Ovarian Neoplasms 1Obesity 1Lethal Congenital Contracture Syndrome 2 1Joint Diseases 1Invasive Breast Cancer 1Hypogonadism 1Granulosa Cell Ovarian Cancer 1Fractures, Bone 1Erectile Dysfunction 1Epilepsy 1Bone Diseases, Metabolic 1Bone Density 1

Interventions

seribantumab 2zenocutuzumab 1patritumab 1exemestane 1Vinorelbine 1Trastuzumab 1Letrozole 1In Situ Hybridization, Fluorescence 1Fulvestrant 1Erlotinib Hydrochloride 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lethal Congenital Contracture Syndrome 2 × Anastrozole × Clear all
NCT03321981 2024-03-07

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Merus B.V.

Phase 2 Completed
105 enrolled 23 charts

Lethal Congenital Contracture Syndrome 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡